Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year.
Musialik
Joanna
J
Department of Internal Medicine, Medical University of Silesia, St. Barbara Hospital, Sosnowiec, Poland. Joanna@sla.com.pl
Petelenz
Michal
M
Gonciarz
Zbigniew
Z
D015502:Absorptiometry, Photon; D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D011336:Probability; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
D019386:Alendronate